Our portfolio spans the full continuum covering chronic conditions such as asthma, COPD, interstitial lung disease (ILD) and everyday conditions like cough, rhinitis, and allergies.

We offer one of the industry’s most advanced devices from Dry Powder Inhalers (DPI), Metered Dose Inhalers (MDI), to nasal sprays and nebulisation. We are driving the Respiratory franchise forward by building next-generation products, robust delivery systems, and nebulisation therapies for ease of use and better patient outcomes.

A key innovation in this area is Ryaltris^®, a differentiated fixed-dose nasal spray that combines an antihistamine and a corticosteroid in a single formulation. By addressing both the allergic response and underlying nasal inflammation, Ryaltris^® offers clinically meaningful differentiation in treatment of allergic rhinitis. Designed to support effective symptom control, convenience, and adherence, it reflects our patient-centric approach to respiratory innovation offering clinically meaningful differentiation for the management of seasonal and perennial allergies across global markets.